Pharmacotherapy of first episode psychosis in Estonia: Comparison with national and international treatment guidelines

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 2, 2008, Pages 165-173

  Lass, J ^a   Mannik A ^b   Bell, J S ^c  

^a TARTU UNIVERSITY HOSPITAL   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adherence to the treatment guidelines; Mental health; Pharmacotherapy

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; DIAZEPAM; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DELUSIONAL DISORDER; DRUG MEGADOSE; FEMALE; HOSPITAL ADMISSION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MENTAL HOSPITAL; MONOTHERAPY; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; ESTONIA; FEMALE; HEALTH POLICY; HOSPITALS; HUMANS; INTERNATIONALITY; MALE; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 40349088708     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00900.x     Document Type: Article

References (45)

1. De Oliveira IR, Juruena MF (2006) Treatment of psychosis: 30 years of progress. Journal of Clinical Pharmacy and Therapeutics, 31, 523 530.
2. Byrne P (2007) Managing the acute psychotic episode. British Medical Journal, 334, 686 692.
3. Perkins DO, Gu H, Boteva K, Lieberman JA (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry, 162, 1785 1804.
4. Barnes TRE, Hutton SB, Chapman MJ, Mutsatsa S, Puri BK, Joyce EM (2000) West London first-episode study of schizophrenia. British Journal of Psychiatry, 177, 207 211.
5. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders (2004) Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Available at: http://www.ranzcp.org/pdffiles/cpgs/ Clinician%20version%20full%20schizophrenia.pdf (accessed 12 November 2007).
6. National Collaborating Centre for Mental Health (2003) Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. Available at: http://www.nice.org.uk/nicemedia/pdf/cg001fullguideline.pdf (accessed 12 November 2007).
7. American Psychiatric Association (2003) Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. Available at: http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf (accessed 12 November 2007).
8. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS (2005) Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry, 187, 248 255.
9. Eesti Psühhiaatrite Selts (2000) Skisofreenia ravijuhis [in Estonian]. Available at: http://www.kliinikum.ee/psyhhiaatriakliinik/Programm/ ravi/ps-ravi/SCH/skisofreenia_ravijuhis.htm (accessed 23 September 2006).
10. Dickey B, Normand SLT, Hermann RC, Eisen SV, Cortes DE, Cleary PD, Ware N (2003) Guideline Recommendations for Treatment of Schizophrenia. Archives of General Psychiatry, 60, 340 348.
11. West JC, Wilk JE, Olfson M et al. (2005) Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatric Services, 56, 283 291.
12. Gisev N, Bell JS, McLachlan AJ, Chetty M, Chen TF (2006) Psychiatric drug use among patients of a Community Mental Health Service. Disease Management and Health Outcomes, 14, 369 376.
13. Wilkie A, Preston N, Wesby R (2001) High dose neuroleptics - who gives them and why? Psychiatric Bulletin, 25, 179 183.
14. Harrington M, Lelliott P, Paton C, Okocha C, Duffet R, Sensky T (2002) The results of a multi-centre audit of the prescribing of antipsychotic drugs for in- patients in the UK. Psychiatric Bulletin, 26, 414 418.
15. Kiivet RA, Llerena A, Dahl MA, Rootslane L, Vega JS, Eklundh T, Sjöqvist F (1995) Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. British Journal of Clinical Pharmacology, 40, 467 476.
16. Bowers L, Callaghan P, Clark N, Evers C (2004) Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. European Journal of Clinical Pharmacology, 60, 29 35.
17. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin, 28, 75 84.
18. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54, 55 59.
19. Covell NH, Jackson CT, Evans AC, Essock SM (2002) Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin, 28, 17 29.
20. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C (2002) The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26, 411 414.
21. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin B (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry, 65, 1377 1388.
22. Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophrenia Bulletin, 30, 1023 1033.
23. Centorrino F, Eakin M, Bahk WM et al. (2002) Inpatient antipsychotic drug use in 1998, 1993, and 1989. American Journal of Psychiatry, 159, 1932 1935.
24. Broekema WJ, de Groot IW, van Harten PN (2007) Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - a European study. Pharmacy World and Science, 29, 126 130.
25. Sim K, Su A, Fujii S et al. (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58, 178 183.
26. Simon AE, Peter M, Hess L, Valterio C (2005) Antipsychotic use in patients with schizophrenia treated in private psychiatry. Swiss Medical Weekly, 135, 109 115.
27. Kogut SJ, Yam F, Dufresne R (2005) Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. Journal of Managed Care Pharmacy, 11, 17 24.
28. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry, 5, 1 11.
29. Ito H, Koyama A, Higuchi T (2005) Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. British Journal of Psychiatry, 187, 243 247.
30. Sohler NL, Walkup J, McAlpine D, Boyer C, Olfson M (2003) Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatric Services, 54, 1258 1263.
31. Miller AL, Craig CS (2002) Combination antipsychotics: pros, cons, and questions. Schizophrenia Bulletin, 28, 105 109.
32. Kingsbury SJ, Yi D, Simpson GM (2001) Rational and irrational polypharmacy. Psychiatric Services, 52, 1033 1035.
33. Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325 329.
34. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122 127.
35. Weissman EM (2002) Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophrenia Bulletin, 28, 31 42.
36. Polubinskaya SV (2000) Reform in psychiatry in post-soviet countries. Acta Psychiatria Scandinavica, 100, 106 108.
37. World Health Organization (2007) World Health Organization Project Atlas: Resources for Mental Health - Country Profile Estonia. Available at: http://www.who.int/mental_health/evidence/atlas/profiles_countries_e_i.pdf (accessed 20 September 2007).
38. Ministry of Social Affairs (2007) Statistics. Available at: http://www.sm.ee/est/Htmlpages/Kolmas/$file/kolmas.xls (accessed 16 May 2007).
39. British Medical Association and The Royal Pharmaceutical Society of Great Britain (2007) The British National Formulary No.53. Electronic Version. Available at: http://www.bnf.org/bnf/ (accessed 12 March 2007).
40. Royal College of Psychiatrists (2006) Consensus Statement on High-Dose Antipsychotic Medication. Available at: http://www.rcpsych.ac.uk/files/ pdfversion/CR138.pdf (accessed 12 November 2007).
41. Haw C, Stubbs J (2003) Combined antipsychotics for 'difficult-to manage' and forensic patients with schizophrenia: reasons for prescribing and perceived benefits. Psychiatric Bulletin, 27, 449 452.
42. Barbui C, Nose M, Mazzi M et al. (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21, 355 362.
43. Morrato EH, Dodd S, Oreda G et al. (2007) Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid Population, 1998-2003. Clinical Therapeutics, 29, 183 195.
44. Baldwin P, Browne D, Scully PJ et al. (2005) Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan- Monaghan study at 8 years. Schizophrenia Bulletin, 31, 624 638.
45. Norman RMG, Malla AK (2001) Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine, 31, 381 400.